Novel Medical therapy using Telomerase Inhibitor TMPyP4 for Osteosarcoma

2014 Fiscal Year Final Research Report

• Project/Area Number: 25861322
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Orthopaedic surgery
• Research Institution: Hiroshima University
• Principal Investigator: FUJIMORI Jun 広島大学, 大学院医歯薬保健学研究院(医), 寄附講座助教 (70632256)
• Research Collaborator: SHIMOSE Shouji 広島大学, 大学院医歯薬学総合研究科, 准教授 (30304439) ; KUBO Tadahiko 広島大学, 病院, 講師 (70397959)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: テロメラーゼ阻害剤 / テロメア / 骨肉腫

Outline of Final Research Achievements

In this study, we investigated the antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. Both telomerase activity loss and sufficient telomere shortening are necessary to inhibit cell growth in telomerase positive cells. TMPyP4 did not induce telomere shortening but significantly inhibited the growth in extremely longer telomere-cells, indicating the antitumor effect of TMPyP4 may be related to DNA damage, independent on telomere length. Our results may indicate telomerase inhibitors such asTMPyP4 are novel adjuvant therapy for osteosarcoma patients in the near future.

Free Research Field

骨軟部腫瘍